PIs

Goro Sashida
M.D., Ph.D.
Professor

ACHIEVEMENT

Selected Research Articles:

  1. Kubota S, Sun Y, Morii M, Bai J, Ideue T, Hirayama M, Sorin S, Eerdunduleng, Yokomizo-Nakano T, Osato M, Hamashima A, Iimori M, Araki K, Umemoto T, Sashida G*. EMBO Chromatin modifier Hmga2 promotes adult hematopoietic stem cell function and blood regeneration in stress conditions. EMBO J 2024; 43(13): 2661-2684.
  2. Morii M, Kubota S, Iimori M, Yokomizo-Nakano T, Hamashima A, Bai J, Nishimura A, Tasaki M, Ando Y, Araki K, Sashida G*. TIF1β activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia. Leukemia 2024; 38(6): 1275-1286.
  3. Yokomizo-Nakano T, Hamashima A, Kubota S, Bai J, Sorin S, Sun Y, Kikuchi K, Iimori M, Morii M, Kanai A, Iwama A, Huang G, Kurotaki D, Takizawa H, Matsui H, Sashida G*. Exposure to microbial products followed by loss of Tet2 promotes myelodysplastic syndrome via remodeling HSCs. J Exp Med 2023; 220(7): e20220962.
  4. Umemoto T, Johansson A, Ahmad SAI, Hashimoto M, Kubota S, Kikuchi K, Odaka H, Era T, Kurotaki D, Sashida G, Suda T*. ATP citrate lyase controls hematopoietic stem cell fate and supports bone marrow regeneration. EMBO J 2022. 41(8): e109463.
  5. Abdallah MG, Niibori-Nambu A, Morii M, Yokomizo T, Yokomizo T, Ideue T, Kubota S, Teoh VSI, Mok MMH, Wang CQ, Omar AA, Tokunaga K, Iwanaga E, Matsuoka M, Asou N, Nakagata N, Araki K, AboElenin M, Madboly SH, Sashida G*, Osato M*. RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner. Leukemia 2021. 35(10): 2983-2988.
  6. Bai J, Yokomizo-Nakano T, Kubota S,  Sun Y, Kanai A, Iimori M, Harada H, Iwama A, Sashida G*. Overexpression of Hmga2 activates Igf2bp2 and remodles transcriptional program of Tet2-deficient stem cells in myeloid transformation. Oncogene 2021; 40(8): 1531-1541.
  7. Shide K, Kameda T, Kamiunten A, Ozono Y, Tahira Y, Yokomizo-Nakano T, Kubota S, Ono M, Ikeda K, Sekine M, Akizuki K, Nakamura K, Hidaka T, Kubuki Y, Iwakiri H, Hasuike S, Nagata K, Sashida G, Shimoda K*. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. Blood 2020; 136(1): 106-118.
  8. Yokomizo-Nakano T, Kubota S, Bai J, Hamashima A, Morii M, Sun Y, Katagiri S, Iimori M, Kanai A, Tanaka D, Oshima M, Harada Y, Ohyashiki K, Iwama A, Harada H, Osato M, Sashida G*. Overexpression of RUNX3 represses RUNX1 to drive transformation of myelodysplastic syndrome. Cancer Res 2020; 80(12): 2523-2536.
  9. Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M*, Sashida G*. Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm. Nature Commun 2019; 10: 1653.
  10. Wang C, Oshima M, Sato D, Matsui H, Kubota S, Aoyama K, Nakajima-Takagi Y, Koide S, Matsubayashi J, Mochizuki-Kashio M, Nakano-Yokomizo T, Bai J, Nagao T, Kanai A, Iwama A*, Sashida G*. Ezh2 loss propagates hypermethylation at T-cell differentiation-regulating genes to promote leukemic transformation. J Clin Invest 2018; 128(9): 3872-3886.
  11. Sashida G*, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, Mochizuki-Kashio M, Harada H, Shimoda K, Iwama A*. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med 2016; 213(8): 1459-1477.
  12. Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, Wang C, Iwama A*.  Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-depenedent manner.  Blood 2015; 126(10): 1172-83.
  13. Wang C, Sashida G, Saraya A, Ishiga R, Koide S, Oshima M, Isono K, Koseki H, Iwama A*. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia. Blood 2014; 123(21): 3336-43.
  14. Sashida G*, Harada H, Matsui H, Oshima M, Yui M, Harada Y, Tanaka S, Mochizuki-Kashio M, Wang C, Saraya A, Muto T, Hayashi Y, Suzuki K, Nakajima H, Inaba T, Koseki H, Huang G, Kitamura T, Iwama A*. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nature Commun 2014; 5: 4177.
  15. Muto T#, Sashida G#, Oshima M#, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A*. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013; 210(12): 2627-39. #equal contribution
  16. Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, Koseki H, Iwama A*. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012; 120(5): 1107-17.
  17. Zhang Y#, Yan X#, Sashida G#, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, Grimes HL, Caligiuri MA, Huang G*. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood 2012; 120(5): 1118-29. #equal contribution
  18. Sashida G, Bae N, Di Giandomenico S, Asai T, Gurvich N, Bazzoli E, Liu Y, Huang G, Zhao X, Menendez S, Nimer SD*. The Mef/Elf4 transcription factor finetunes the DNA damage response. Cancer Res 2011; 71(14): 4857-65.
  19. Sashida G, Liu Y, Elf S, Miyata Y, Ohyashiki K, Izumi M, Menendez S, Nimer SD*. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. Mol Cell Biol 2009; 29(13): 3687-99.
  20. Sashida G*, Ohyashiki JH, Nakajima A, Sumi M, Kawakubo K, Tauchi T, Ohyashiki K. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 2003; 9: 1489-1496.

Selected Reviews:

  1. Yokomizo-Nakano T, Sashida G*. Two faces of RUNX3 in myeloid transformation. Exp Hematol 2021; 97: 14-20.
  2. Sashida G, Oshima M, Iwama A*. Deregulated Polycomb functions in myeloproliferative neoplasms. Int J Hematol 2019; 110(2): 170-178.
  3. Sashida G*, Iwama A*. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. Int J Hematol 2017; 105(1): 23-30.
  4. Sashida G, Iwama A*. Epigenetic regulation of hematopoiesis. Int J Hematol 2012; 96(4): 405-12.
  5. Ohyashiki JH*, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002; 21: 680-687.

Guest Editor:

  1. Sashida G*. Recent advance in MDS research. Exp Hematol 2024. Comments on Cammenga, Exp Hematol 2024; Nishimura K, et al. Exp Hematol 2024; Xu JJ, Viny AD, Exp Hematol 2024; Merz AMA, Platzbecker U. Exp Hematol 2024.
  2. Sashida G*. Stem cell regulation and dynamics in myeloid malignancies. Int J Hematol 2023 Jun;117(6):789-790. Comments on Fang Y-C, et al. Int J Hematol 2023; Hayashi Y, et al. Int J Hematol 2023; Jin Z, et al. Int J Hematol 2023; Abdallah MG, et al. Int J Hematol 2023.

Link to a complete list of Goro Sashida's publications.